Clinical trials: Analgesic
Back Pain
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
This study investigates if Celebrex is as effective as tramadol hydrochloride (Ultram) for patients with chronic low back pain, when administered over a 6-week period.
- Trial name
- NCT00290901
- Testing
- Tramadol Hydrochloride 50mg, Celebrex 200mg
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain
Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients
The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting.
- Trial name
- NCT06364072
- Testing
- CT001
- Where
- 7 sites in Spain, United Kingdom
- Volunteers
- 155 people
- Sponsor
- Cessatech A/S
Leukemia, Leukemia, Myeloid
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
This study will find the maximum tolerated dose or the maximum planned dose of CYNK-001 which contains natural killer (NK) cells derived from human placental CD34+ cells and culture-expanded.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type
- Trial name
- CYNK001AML01 (NCT04310592)
- Testing
- CYNK-001
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- Celularity Incorporated
Pain
Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar
To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an…
- Trial name
- NCT02183051
- Testing
- Meloxicam 7.5 mg, Meloxicam 3.75 mg, Meloxicam 1.875 mg
- Volunteers
- 381 people
- Sponsor
- Boehringer Ingelheim
Cancer, Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain…
- Trial name
- NCT01006356
- Testing
- Hydromorphone HCl OROS
- Volunteers
- 141 people
- Sponsor
- Janssen Korea, Ltd., Korea
Knee Osteoarthritis
Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis
The primary objective of this study is to evaluate the efficacy and safety of glucosamine sulfate versus placebo on the symptoms of knee osteoarthritis after 6 months of treatment, using acetaminophen as a reference symptomatic…
- Trial name
- NCT00110474
- Testing
- Glucosamine sulfate, Acetaminophen
- Where
- 13 sites in Portugal, Spain
- Volunteers
- 300 people
- Sponsor
- Rottapharm
Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years, inclusive, with moderate to severe malignant…
- Trial name
- NCT01192295
- Testing
- Oxycodone HCl controlled-release tablets
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 155 people
- Sponsor
- Purdue Pharma LP
Healthy
Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations
The purpose of this study is to determine whether Transtec (R) PRO 70 µg/h and a new buprenorphine patch formulation lead to same plasma levels of buprenorphine after single dose application
- Trial name
- NCT00388219
- Testing
- Transtec (R) PRO (buprenorphine)
- Where
- 2 sites in Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Dental Pain
A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction
This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety.
- Trial name
- NCT00663767
- Testing
- ARRY-371797, p38 inhibitor; oral, Celecoxib, COX-2 inhibitor; oral
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- Pfizer
Peripheral Analgesic and Anti-itch
Pharmacokinetics, Mass Balance, and Metabolism of [14C]HSK21542 in Healthy Adult Male Volunteers.
This is a single-center, nonrandomized, and open design study to investigate the pharmacokinetics, mass balance, metabolism and excretion of HSK21542 in healthy male subjects.
- Trial name
- NCT05835934
- Testing
- [14C]HSK21542
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Central Neuropathic Pain in Multiple Sclerosis
Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients.
- Trial name
- NCT00959218
- Testing
- Dronabinol
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- Bionorica Research GmbH
Pain, Post Surgical
A Multicenter, Open Label Trial To Evaluate Pain Relief With Intravenous Followed By Oral Therapy With Parecoxib/Valdecoxib 40 Mg/Day For Treatment Of Post-Laparoscopic Surgery Pain
The objectives of this study were to assess the analgesic efficacy and safety of parecoxib/valdecoxib on post-laparoscopic surgery analgesia.
- Trial name
- NCT00660855
- Testing
- parecoxib/valdecoxib
- Where
- 2 sites in Argentina
- Volunteers
- 4 people
- Sponsor
- Pfizer
Analgesia
Comparison of Analgesic Effect and Prognosis of Butorphanol and Fentanyl in Patients With Mechanical Ventilation
ICU patients often in a strong stress environment. Various invasive procedures such as wound dressing change, sputum suction,Pull out the thoracic duct etc.
- Trial name
- NCT04315935
- Testing
- Butorphanol and Propofol, Fentanyl and Propofol
- Where
- China
- Volunteers
- 355 people
- Sponsor
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
Acute Pain
Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain
The purpose of this study is to evaluate the analgesic efficacy and safety of two doses of oxymorphone immediate release (IR) compared to placebo and oxycodone in post-surgical pain.
- Trial name
- NCT00226395
- Testing
- Oxymorphone immediate release
- Where
- 21 sites in United States
- Volunteers
- 320 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Pain, Postoperative Arthroscopy
Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)
Study the effect of rofecoxib 50 mg compared to both placebo, and hydrocodone 7.5 mg with acetaminophen 750 mg, to treat moderate to severe pain following arthroscopic knee surgery.
- Trial name
- NCT00390260
- Testing
- MK0966 / Duration of Treatment: 1 Days, Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Laparoscopic Surgery
Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery
The purpose of this study is to determine the analgesic efficacy and safety of N1539 in subjects undergoing abdominal laparoscopic surgery.
- Trial name
- NCT01436032
- Testing
- N1539, Ketorolac Tromethamine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alkermes, Inc.
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Osteoarthritis
A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED)
This study will evaluate a walking model of osteoarthritis for use in testing of new therapeutic agents. The primary hypothesis is that participants treated with Naproxen or Ultracet will have lower Pain Intensity (PI) than those…
- Trial name
- NCT00772967
- Testing
- Naproxen, Ultracet
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral Nervous System Diseases, Pain
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
The purpose of the study is to assess the efficacy and safety of NGX-4010 applied for 60 minutes for the treatment of postherpetic neuralgia (PHN).
- Conditions
- Peripheral Nervous System Diseases, Pain, Neuralgia, Herpes Zoster
- Trial name
- NCT00300222
- Testing
- NGX-4010
- Volunteers
- 400 people
- Sponsor
- NeurogesX
Osteoarthritis, Arthritis
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating…
- Trial name
- NCT00809354
- Testing
- NSAID, tanezumab
- Where
- 333 sites in United States, Canada and 10 more
- Volunteers
- 2,720 people
- Sponsor
- Pfizer